The Q3 2016 EPS Estimates for Astrazeneca PLC Decreased by Analyst (AZN)

The Q3 2016 EPS Estimates for Astrazeneca PLC Decreased by Analyst (AZN)

Astrazeneca PLC (NYSE:AZN) – Stock analysts at Leerink Swann dropped their Q3 2016 earnings estimates for shares of Astrazeneca PLC in a note issued to investors on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will post earnings of $0.47 per share for the quarter, down from their prior forecast of $0.56. Leerink Swann currently has a “Hold” rating and a $35.00 price target on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2018 earnings at $2.06 EPS.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. During the same period in the previous year, the company posted $1.21 earnings per share. The firm’s revenue was down 4.0% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on AZN. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a research report on Tuesday, June 14th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research report on Saturday, June 25th. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, June 27th. Argus initiated coverage on Astrazeneca PLC in a research report on Tuesday, July 12th. They set a “hold” rating on the stock. Finally, Bank of America Corp. restated a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a research report on Monday, July 18th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $37.56.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Monday. The company has a market capitalization of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75. The company’s 50 day moving average price is $33.23 and its 200 day moving average price is $30.79. Astrazeneca PLC has a 52-week low of $26.97 and a 52-week high of $35.04.

The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.

Several hedge funds have recently bought and sold shares of AZN. Forester Capital Management LTD boosted its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the last quarter. First Interstate Bank boosted its stake in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares during the last quarter. Synovus Financial Corp boosted its stake in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. Fifth Third Bancorp boosted its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares during the last quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca PLC Company Profile

Related posts

Leave a Comment